Adma Biologics rose 9% pre-market after pushing back against a Culper short report as "unsubstantiated." The firm defended Asceniv demand, citing steady growth over two years. ADMA also denied channel stuffing allegations, arguing distributor inventory levels align with industry norms and reflect normal supply dynamics rather than excess.